1. Home
  2. MURA vs CLGN Comparison

MURA vs CLGN Comparison

Compare MURA & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MURA
  • CLGN
  • Stock Information
  • Founded
  • MURA 2013
  • CLGN 2004
  • Country
  • MURA Ireland
  • CLGN Israel
  • Employees
  • MURA N/A
  • CLGN N/A
  • Industry
  • MURA
  • CLGN Industrial Specialties
  • Sector
  • MURA
  • CLGN Health Care
  • Exchange
  • MURA Nasdaq
  • CLGN Nasdaq
  • Market Cap
  • MURA 57.2M
  • CLGN 51.3M
  • IPO Year
  • MURA N/A
  • CLGN N/A
  • Fundamental
  • Price
  • MURA $3.20
  • CLGN $3.77
  • Analyst Decision
  • MURA Strong Buy
  • CLGN Strong Buy
  • Analyst Count
  • MURA 4
  • CLGN 2
  • Target Price
  • MURA $16.00
  • CLGN $12.50
  • AVG Volume (30 Days)
  • MURA 270.3K
  • CLGN 13.2K
  • Earning Date
  • MURA 11-13-2024
  • CLGN 11-27-2024
  • Dividend Yield
  • MURA N/A
  • CLGN N/A
  • EPS Growth
  • MURA N/A
  • CLGN N/A
  • EPS
  • MURA N/A
  • CLGN N/A
  • Revenue
  • MURA N/A
  • CLGN $650,000.00
  • Revenue This Year
  • MURA N/A
  • CLGN N/A
  • Revenue Next Year
  • MURA N/A
  • CLGN $692.59
  • P/E Ratio
  • MURA N/A
  • CLGN N/A
  • Revenue Growth
  • MURA N/A
  • CLGN N/A
  • 52 Week Low
  • MURA $2.88
  • CLGN $3.31
  • 52 Week High
  • MURA $6.25
  • CLGN $6.99
  • Technical
  • Relative Strength Index (RSI)
  • MURA 32.85
  • CLGN 34.26
  • Support Level
  • MURA $3.50
  • CLGN $3.60
  • Resistance Level
  • MURA $4.20
  • CLGN $4.17
  • Average True Range (ATR)
  • MURA 0.25
  • CLGN 0.19
  • MACD
  • MURA -0.09
  • CLGN -0.05
  • Stochastic Oscillator
  • MURA 1.96
  • CLGN 2.26

About MURA Mural Oncology plc

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.

About CLGN CollPlant Biotechnologies Ltd

CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.

Share on Social Networks: